Coagulase-negative staphylococci release a purine analog that inhibits *Staphylococcus aureus* virulence

Denny Chin¹, Mariya I. Goncheva¹, Ronald S. Flannagan¹, Shayna R. Deecker², Veronica Guariglia-Oropeza¹, Alexander W. Ensminger²,³ & David E. Heinrichs¹

Coagulase-negative staphylococci and *Staphylococcus aureus* colonize similar niches in mammals and conceivably compete for space and nutrients. Here, we report that a coagulase-negative staphylococcus, *Staphylococcus chromogenes* ATCC43764, synthesizes and secretes 6-thioguanine (6-TG), a purine analog that suppresses *S. aureus* growth by inhibiting de novo purine biosynthesis. We identify a 6-TG biosynthetic gene cluster in *S. chromogenes* and other coagulase-negative staphylococci including *S. epidermidis, S. pseudintermedius* and *S. capitis*. Recombinant *S. aureus* strains harbouring this operon produce 6-TG and, when used in subcutaneous co-infections in mice with virulent *S. aureus* USA300, protect the host from necrotic lesion formation. Used prophylactically, 6-TG reduces necrotic skin lesions in mice infected with USA300, and this effect is mediated by abrogation of toxin production. RNAseq analyses reveal that 6-TG downregulates expression of genes coding for purine biosynthesis, the accessory gene regulator (agr) and ribosomal proteins in *S. aureus*, providing an explanation for its effect on toxin production.
*Staphylococcus aureus* is an opportunistic human pathogen and a significant cause of morbidity and mortality worldwide, causing a wide spectrum of diseases ranging from superficial skin and soft tissue infections to severe life-threatening diseases such as endocarditis and pneumonia. The enormous health burden caused by *S. aureus* is, in part, attributed to its ability to acquire resistance against several classes of antibiotics, making it refractory to many treatment options. Moreover, methicillin-resistant *S. aureus* (MRSA) can infect both healthy and immunocompromised populations in the community and hospital settings. Due to the emergence of MRSA, drug discovery is critically important for combating *S. aureus* infections.

To identify compounds that antagonize *S. aureus*, several groups have focused on coagulase-negative staphylococcal species (CoNS) as many of these species often colonize the same niches as *S. aureus* and likely compete for space and nutrients. To successfully compete with *S. aureus*, CoNS have been shown to secrete antimicrobials that directly kill *S. aureus*. Indeed, strain of *S. epidermidis* and *S. hominis* species; among others, have been reported to secrete posttranslationally modified peptides termed bacteriocins that inhibit *S. aureus* colonization on human skin. In addition, *Staphylococcus lugdunensis* has recently been shown to produce the non-ribosomally synthesized cyclic peptide antibiotic termed lugdunin that directly kills *S. aureus*. Moreover, lugdunin can stimulate host production of antimicrobial peptides and recruit immune cells to clear *S. aureus* infections. Another strategy used by some CoNS including *S. schleiferi* and *S. caprae* is the secretion of autoinducing peptides that specifically block the activation of the agr quorum sensing system in *S. aureus*. By doing so, these CoNS reduce *S. aureus* virulence and interfere with colonization of the host. Clearly, CoNS have evolved mechanisms to antagonize *S. aureus* growth and virulence to gain a competitive advantage.

*S. chromogenes* is a CoNS that can secrete antimicrobials to antagonize *S. aureus* and other bacteria. Here, we show that *S. chromogenes* ATCC43764 secretes the purine analog 6-thioguanine (6-TG) to impede *S. aureus* growth. The underlying genetic basis for 6-TG biosynthesis was elucidated in *S. chromogenes* as a six-gene operon, termed tgs operon for thioguanine synthesis; the tgs operon was also identified in the genomes of a number of *S. capitis*, *S. pseudintermedius*, and *S. epidermidis* strains. We show that the operon from tgs-positive CoNS strains encodes 6-TG, which is inhibitory to *S. aureus*. This was shown to be the case in vivo as well, as co-infections of virulent *S. aureus* USA300 with tgs-positive *S. epidermidis* or *S. aureus* RN4220 (a cloning strain) carrying tgs genes on a plasmid demonstrated a significant reduction in skin lesion necrosis. Moreover, 6-TG reduced *S. aureus* disease severity in a subcutaneous murine infection model, owing to its effect on downregulating toxin production by *S. aureus*. The therapeutic effects of 6-TG are due to its ability to reduce gene expression of the agr quorum sensing system, ribosomal proteins, and purine biosynthesis. This study identifies a mechanism by which CoNS interfere with growth and virulence of *S. aureus*.

**Results**

*S. chromogenes* ATCC43764 inhibits *S. aureus* by secreting 6-TG. To identify CoNS that antagonize the community-acquired MRSA strain *S. aureus* USA300-LAC (hereafter termed *S. aureus*), we screened a number of CoNS using the simultaneous antagonism assay (Supplementary Table 1 and Fig. 1a). Among the species and strains screened, we found that *S. chromogenes* strain ATCC43764, the type strain for the species, inhibited *S. aureus* growth on tryptic soy agar (TSA). We next demonstrated that the inhibitory molecule was secreted as spent culture supernatant (hereafter termed supernatant) of *S. chromogenes* also inhibited growth of *S. aureus* in liquid culture (Fig. 1b). The secreted molecule with inhibitory activity was found to be <3 kDa and resistant to heat and proteases (Supplementary Fig. 1A–D). For identification, the active molecule in *S. chromogenes* supernatant was enriched using sequential steps of centrifcon filtration, FPLC, and, finally, HPLC. Following HPLC, several contiguous fractions antagonized *S. aureus* growth equally (Supplementary Fig. 2A). These fractions were then analyzed by mass spectrometry in three independent experiments (Supplementary Table 2) to identify molecules present. We calculated a “score ratio” of these molecules to determine the relative abundance of these compounds across contiguous fractions within each experiment and found three molecules present in relatively equal abundance in biologically active fractions between experiments. Using these criteria, 6-TG (tioguanine; thioguanine), cinnamic acid, and indoleacrylic acid were the best candidate molecules (Supplementary Table 2). Indoleacrylic acid exerts anti-inflammatory activity and promotes intestinal barrier function and, based on this, we surmised it was unlikely to antagonize *S. aureus* growth. Interestingly, 6-TG and cinnamic acid have previously been shown to inhibit bacterial growth. While cinnamic acid had no inhibitory effect on *S. aureus*, 6-TG impaired *S. aureus* growth on TSA (Supplementary Fig. 2B). Taken together these data suggest that the inhibitory molecule secreted by *S. chromogenes* is 6-TG (Fig. 2a).

**Identification of the 6-TG biosynthetic gene cluster in *S. chromogenes* ATCC43764**

Next we sought to determine the genetic basis of 6-TG biosynthesis in *S. chromogenes* ATCC43764. To date, only *Erwinia amylovora*, a Gram-negative pathogen, has been shown to synthesize 6-TG, attributable to the four-gene yf operon. Hence, we sequenced and annotated the *S. chromogenes* ATCC43764 genome to mine for encoded proteins with predicted functional domains similar to YcFa and YcFB from *E. amylovora*, which are necessary and sufficient for 6-TG biosynthesis. Using InterPro to predict functional protein domains, we identified Rossmann-like alpha/beta-alpha folds and an adenine nucleotide hydrolyase-like domain in YcFa and NADH pyrophosphatase and NUDIX hydroxylase domains in YcB. Interestingly, we found two gene products with identical functional domains within a predicted six-gene operon in the *S. chromogenes* ATCC43764 genome (Fig. 2b). Examination of the predicted products of each of the six genes within the operon (see Table 1) suggest roles in sulfur transfer, nucleotide metabolism, and secretion/efflux.

To prove this operon in *S. chromogenes* was responsible for synthesizing 6-TG, we attempted to delete it from the *S. chromogenes* genome. Unfortunately, we were unable to transform the bacterium using existing plasmids and thus we were unable to genetically modify *S. chromogenes* using traditional molecular genetic methodologies. In lieu of this, we thus amplified and then cloned the genes from *S. chromogenes* into a plasmid and introduced this recombinant plasmid into *S. aureus* RN4220, creating a strain termed RN4220 pTgs. Remarkably, we showed that RN4220 pTgs inhibited *S. aureus* growth on TSA while RN4220 carrying an empty vector (termed RN4220 pEmpty) did not impair *S. aureus* growth (Fig. 2c). Moreover, supernatant from RN4220 pTgs inhibited *S. aureus* growth whereas supernatant from RN4220 pEmpty did not (Fig. 2d). Mass spectrometry was used to confirm that supernatants from RN4220 pTgs, but not RN4220 pEmpty, contained 6-TG (Supplementary Fig. 2C). Taken together, these data identify the genetic basis of 6-TG biosynthesis in *S. chromogenes* ATCC43764.
Fig. 1 *S. chromogenes* secretes a molecule that inhibits *S. aureus* growth. a Simultaneous antagonism assay of selected representative CoNS on TSA. b *S. aureus* was cultured in TSB containing spent culture supernatant from *S. chromogenes* or *S. aureus*. The bacteria were grown for 24 h before they were plated and CFU/mL were enumerated. Results are pooled from three independent experiments. Data are shown as mean ± SD (n = 3, *p ≤ 0.05, ****p ≤ 0.0001. Two-sided unpaired t-test).

Fig. 2 Identification of a 6-TG biosynthetic gene cluster in *S. chromogenes*. a Molecular structure of 6-thioguanine. b *E. amylovora* ycf operon and *S. chromogenes* 6-TG biosynthetic operon. c Simultaneous antagonism assay using RN4220 pEmpty and ptgs on TSA. d *S. aureus* was cultured in TSB containing supernatant from RN4220 pEmpty or ptgs and plated 24 h.p.i and CFU/mL were enumerated. Results are pooled from two independent experiments, each with n = 3 replicates per condition. Data are shown as mean ± SD (**p ≤ 0.01. Two-sided unpaired t-test).

Table 1 Putative function of gene products in the *S. chromogenes* 6-TG biosynthetic cluster.

| Protein | Predicted function | e.g., homolog; organism | Confidence (%) | Coverage (%) |
|---------|--------------------|--------------------------|----------------|-------------|
| TgsA    | PLP-dependent cysteine desulfurase | SufS; *Bacillus subtilis* | 100            | 96          |
| TgsB    | Nucleotide alpha hydrolase; sulfur transferase | TtuA; *Thermus thermophilus* | 100            | 97          |
| TgsC    | NUDIX hydrolase family protein; DNA mismatch repair; pyrophosphatase | MutT; *Bacillus halodurans* | 99.9           | 100         |
| TgsD    | Membrane protein; efflux | EmrE; *E. coli* | 100            | 95          |
| TgsE    | NUDIX hydrolase family protein; DNA mismatch repair; 8-oxo-dGTP diprophosphatase | MutT; *Mycobacterium smegmatis* | 99.9           | 89          |
| TgsF    | Haloacid dehalogenase-like hydrolase; phosphatase | YfnB; *Bacillus subtilis* | 100            | 92          |

*Phyre2*; the protein homology/analogy Recognition Engine v.2.0, web portal was used to search the protein structure databases for predicting protein structure and function.
and confirm that the expression of these genes by this species is detrimental to the growth of S. aureus. The six-gene operon was thus designated tgsA-F, for thioguanine synthesis.

Identification of the tgs operon in other staphylococcal species. Next, we assessed the diversity of the tgs operon and its homologs in publicly available genomes of Staphylococcus species. We surveyed 1388 genomes across seven different species of Staphylococcus and discovered that the operon and its homologs can be found in genomes from S. capitis, S. chromogenes, S. epidermidis, and S. pseudintermedius (Table 2 and Supplementary Data 1). A phylogenetic analysis of these sequences showed that the tgs operon grouped into species-specific clades, suggesting that the operon was acquired by a common ancestor of each species and then passed down via vertical inheritance (Fig. 3a). Interestingly, in S. chromogenes strain 1401, the operon is present on a plasmid, suggesting that it has the potential to be passed between different strains and species via horizontal gene transfer.

To determine whether other CoNS that encode the tgs operon inhibit S. aureus growth in vitro, we tested both tgs-negative and -positive strains that were identified in our bioinformatic analyses using the simultaneous antagonism assay. As expected, the tgs-positive S. epidermidis M23864:W2 strain inhibited growth of S. aureus while the tgs-negative strains did not. However, both tgs-positive S. capitis strains did not inhibit S. aureus growth in our assay conditions (Fig. 3b). This result led us to hypothesize that expression of the tgs operon in these strains was repressed. Thus, to test this hypothesis, we amplified and cloned the tgs operon from one of the S. capitis strains (VCU116) into a plasmid, and introduced this recombinant plasmid into S. aureus RN4220, creating a strain termed RN4220 pVCU116 tgs. Of note, RN4220 pEmpty did not (Fig. 3c, d). Mass spectrometry confirmed that both RN4220 pVCU116 tgs and S. epidermidis M23864:W2 produce 6-TG. Moreover, supernatants from both tgs-positive S. capitis strains had detectable levels of 6-TG, although ~20-fold less than that of RN4220 pVCU116 tgs or the other tgs-positive species that showed growth-inhibitory effects on S. aureus (Supplementary Table 2).
aureus USA300 and co-colonize on human skin11,24. We mixed these species in a subcutaneous infection model, as these strains can offer protection to the host and antagonize virulence in vivo, we performed co-infection experiments using strains of S. aureus. Our results demonstrated that co-infections with a RN4220 pEmpty strain reduced skin damage caused by S. aureus (Fig. 4a, b). Admittedly, these strains were correla-
tive and in subsequent experiments, and irrespective of lesion size, if we excised similar areas of skin from both the vehicle and 6-TG-treated mice we found that, despite significant differences in lesion size between treated vs. untreated groups, similar bacterial burdens were present at 4 days post infection (Fig.5c). The discrepancy in the measured bacterial load using these two methods suggest that quantification of CFUs is more accurate when a large section of the skin is excised, irrespective of the lesion size. Taken together, these data demonstrate that prophylactic treatment with 6-TG significantly reduces necrotic lesion formation caused by S. aureus.

Expression of tgs genes ameliorates S. aureus virulence in vivo. Our results demonstrated that staphylococci that express the tgs operon inhibit S. aureus growth in vitro. To determine whether these strains can offer protection to the host and antagonize S. aureus in vivo, we performed co-infection experiments using S. aureus USA300 and tgs-negative or -positive S. epidermidis strains in a subcutaneous infection model, as these species are known to co-colonize on human skin11,24. We mixed S. aureus with either a tgs-negative or -positive S. epidermidis strain in a 1:1 ratio and measured the size of lesions over time. Importantly, we observed that co-infections with a tgs-positive S. epidermidis strain reduced skin damage caused by S. aureus compared to co-infections with a tgs-negative S. epidermidis strain (Fig. 4a, b). Admittedly, these experiments using different S. epidermidis strains were correla-
tive. However, to demonstrate a causative effect of tgs genes, we repeated these co-infection experiments by combining S. aureus USA300 (produces necrotic lesions) with S. aureus RN4220 (does not produce necrotic lesions) carrying either pEmpty or tgs. Remarkably, we observed that co-infections with RN4220 tgs resulted in significantly smaller lesions compared to co-infections with RN4220 pEmpty (Fig. 4c, d). These data show that staphylococci that express the tgs operon can protect the host against necrotic skin infections caused by S. aureus.

6-TG inhibits tissue necrosis during subcutaneous S. aureus infection. Although co-infections with tgs-positive strains can protect the host against skin damage caused by S. aureus, it is unlikely that these strains can be administered as a probiotic to combat S. aureus infections as these bacteria may also cause infections on their own. Therefore, we sought to assess the therapeutic effect of 6-TG on formation of necrotic skin lesions in a subcutaneous S. aureus infection. To do this, we prophylacti-
cally administered 6-TG subcutaneously and measured the size of lesions throughout infection. Strikingly, we observed that the necrotic lesions of treated mice were significantly smaller than the lesions on mice injected with vehicle control (Fig. 5a, b). Moreover, we observed a reduction in bacterial load when we excised the lesions of mice treated with 6-TG relative to the mice given the vehicle control (Supplementary Fig. 4). However, in addi-
tional to these, similar areas of skin from both the vehicle and 6-TG-treated mice we found that, despite significant differences in lesion size between treated vs. untreated groups, similar bacterial burdens were present at 4 days post infection (Fig. 5c). The discrepancy in the measured bacterial load using these two methods suggest that quantification of CFUs is more accurate when a large section of the skin is excised, irrespective of the lesion size. Taken together, these data demonstrate that prophylactic treatment with 6-TG significantly reduces necrotic lesion formation caused by S. aureus.
6-TG blocks toxin production in S. aureus in a purine-dependent and -independent manner. 6-TG is a guanine analog that is known to inhibit purine biosynthesis. In support of the notion that 6-TG inhibits S. aureus growth by interfering with purine biosynthesis, we show that a S. aureus purK::ΦΝΣ mutant, with a disrupted purine biosynthesis pathway, was largely resistant to 6-TG-mediated growth inhibition on TSA (Supplementary Fig. 5A). Furthermore, 6-TG is more potent against S. aureus grown on purine-deplete RPMI than on TSA (Supplementary Fig. 5A, B). Interestingly, 6-TG is also active against strains representing other S. aureus clonal lineages, although to varying degrees (Supplementary Fig. 6). Taken together, these data indicate that 6-TG primarily impairs S. aureus growth by inhibiting purine biosynthesis.

Since 6-TG abrogated necrosis in the S. aureus subcutaneous infection model, we questioned whether the compound could curtail production of S. aureus secreted toxins, which are required for tissue necrosis in this model. Interestingly, several studies demonstrate a link between purine biosynthesis and S. aureus virulence. To determine whether 6-TG, a purine biosynthesis inhibitor, reduces toxin production, we cultured S. aureus in tryptic soy broth (TSB) with 6-TG or a vehicle control to stationary phase (OD₆₀₀ = 7.0), collected supernatants and analyzed the secreted protein profile using SDS-PAGE. We observed that supernatants from bacteria grown with 6-TG had less overall protein, including several toxins, compared to vehicle treated cultures (Fig. 6a). Next, we chose Hla as a representative S. aureus toxin and evaluated the effects of 6-TG on its levels in S. aureus cultures. Importantly, this toxin is known to be important for S. aureus pathogenesis in skin infections. Here, we used an anti-Hla antibody to confirm that Hla levels were dramatically reduced when S. aureus was exposed to 6-TG (Fig. 6b), and demonstrated that this reduction in Hla was dose-dependent and correlated with its effect on growth (Supplementary Fig. 7A–C).

To determine whether toxin production was abrogated by 6-TG due to its effect on purine biosynthesis, we performed SDS-PAGE on culture supernatants from S. aureus and purK::ΦΝΣ grown in TSB with 6-TG or a vehicle control. Interestingly, we observed that purK::ΦΝΣ secretes less overall protein compared to its wild-type counterpart in the absence of 6-TG, confirming that purine biosynthesis is linked to toxin production in S. aureus. However, purK::ΦΝΣ secretes less overall protein when cultured with 6-TG despite already being deficient in purine biosynthesis (Fig. 6c). A western blot analysis demonstrated that these findings also extend to Hla protein levels in cell culture supernatants (Fig. 6d). We confirmed that the effects of 6-TG on purK::ΦΝΣ were not due to an effect on growth, as the compound does not affect the mutant’s growth kinetics (Supplementary Fig. 8). Overall, these results suggest that 6-TG affects toxin production in both a purine-dependent and -independent manner.

Next, we evaluated the importance of S. aureus purine biosynthesis for necrotic lesion formation in a subcutaneous infection. Here, we prophylactically treated mice with 6-TG or a vehicle control before subcutaneously infecting them with S. aureus or purK::ΦΝΣ. As expected, purK::ΦΝΣ caused smaller necrotic lesions compared to wild-type S. aureus in mice given a vehicle control (Fig. 6e). However, the lesion size caused by this mutant was unaffected by 6-TG, suggesting that a very-low amount of Hla is required for lesion formation and a significant increase in Hla levels is required to increase lesion size (i.e., the relationship between Hla levels and lesion size is not completely linear). Interestingly, purK::ΦΝΣ treated with 6-TG had a slight increase in bacterial burden relative to the control without treatment (Fig. 6f). These data reveal the importance of purine biosynthesis for the regulation of toxin production in S. aureus in a subcutaneous infection model.

6-TG abolishes transcription of ribosomal genes and genes of the pur and agr operons. Next, we wanted to determine the exact changes that 6-TG exerts on S. aureus and to understand how it affects toxin production in both a purine-dependent and -independent manner. To accomplish this, we cultured both wild-type S. aureus and its purK::ΦΝΣ derivative to exponential phase (OD₆₀₀ = 1.0) and exposed them to 6-TG for 1 h before collecting the cells and extracting the RNA to perform RNA sequencing (RNA-seq). Some of the most upregulated genes upon exposure to 6-TG were CodY-regulated genes, such as branched chain amino acid synthesis genes. We attribute this to the effects 6-TG has on repressing guanine levels and, thus, guanosine triphosphate (GTP), which is an effector molecule of CodY DNA binding and thus its transcriptional repression. However, to understand how 6-TG inhibits toxin production in S. aureus, we focused our analyses on transcripts that were repressed by 6-TG. As expected, transcripts from the pur operon were significantly downregulated in wild-type cells treated with 6-TG, owing to the drug’s effect on purine biosynthesis. Surprisingly, transcripts from the agr operon and over 40 genes that encode for ribosomal proteins were also significantly reduced by 6-TG in wild-type cells (Fig. 7a). These results suggest that 6-TG abrogates toxin production in S. aureus in two ways; it downregulates transcription...
from the global virulence regulator agr and it globally reduces protein synthesis by preventing ribosomal proteins from being synthesized, which consequently impedes toxin production. Indeed, 1-h treatment with 6-TG already reduces the expression of hla by 1.65-fold (40%) (Supplementary Data 2). To determine which effects are purine-dependent or -independent, we compared transcript levels between WT and purK::ΦNS in cultures treated and untreated with 6-TG (Fig. 7b). Strikingly, there was a strong overlap in genes that were affected by the purK mutation in S. aureus (Fig. 7b), versus WT treated with 6-TG (Fig. 7a). Indeed, there was a significant reduction in transcripts from the pur operon because purK::ΦNS is inherently deficient in purine synthesis. However, the number of transcripts from genes that encode for many ribosomal proteins was also reduced compared to wild-type cells, suggesting a link between purine biosynthesis and ribosome synthesis. Interestingly, transcripts from the agr operon are reduced to a lesser extent in the purine biosynthesis mutant compared with WT that has been treated with 6-TG (Fig. 7b, c.f. a), suggesting that the effects 6-TG has on agr are not fully purine-dependent. In support of this, transcripts from agr are reduced further when the purK::ΦNS culture is treated with 6-TG relative to the untreated purK::ΦNS culture (Fig. 7c). No significant differences in the number of transcripts were found when comparing the transcriptome of the purK::ΦNS mutant and wild-type cells when both cultures were treated with 6-TG (Fig. 7d). Altogether, these data show that 6-TG drastically reduces ribosome synthesis in a purine-dependent manner and blocks agr activation in both a purine-dependent and -independent manner. As a result, production of proteinaceous toxins will be significantly diminished as translation is blocked by 6-TG.

Discussion

S. aureus is a major human pathogen that causes a spectrum of mild to severe diseases, including self-limiting skin infections to sepsis. The emergence of MRSA has sparked interest in discovering new drugs to combat drug-resistant S. aureus infections. Attention has been focused on CoNS for drug discovery as these species compete against S. aureus in their respective ecological niches. Indeed, CoNS including S. epidermidis, S. hominis, S. lugdunensis, and S. capitis, have been reported to secrete effector molecules to inhibit S. aureus colonization and reduce its virulence. These studies illustrate the importance of CoNS as a potential source of compounds that can be used to treat S. aureus infections.

In this work, we found a strain of S. chromogenes that blocks purine biosynthesis to inhibit S. aureus growth. Importantly, de novo purine biosynthesis has recently been shown to regulate the virulence potential of S. aureus. It is interesting that the tgs operon was found in S. chromogenes because this is a species that co-colonizes with S. aureus in cattle. Since these two species occupy the same ecological niche, it is conceivable that they are in

**Fig. 6 6-TG reduces S. aureus toxin production in a purine-dependent and -independent manner.** a S. aureus was grown in the presence of 6-TG (10 µg/mL) or a vehicle control to an OD600 of 7.0 and secreted proteins in the supernatant were TCA precipitated and separated by SDS-PAGE. This experiment was repeated three times with similar results. b Protein samples in a were immunoblotted and probed with anti-alpha toxin antibody in a Western blot. Protein identification was by MALDI TOF MS. Numbers indicate molecular mass markers. This experiment was repeated three times with similar results. c S. aureus and S. aureus purK::ΦNS was grown in TSA with 6-TG (10 µg/mL) or a vehicle control to an OD600 of 7.0 and secreted proteins in the supernatant were TCA precipitated and separated by SDS-PAGE. This experiment was repeated twice with similar results. d Protein samples in c were immunoblotted and probed with anti-alpha toxin antibody in a Western blot. This experiment was repeated twice with similar results. e Quantitation of necrotic skin lesion size 4 days post infection with S. aureus or S. aureus purK::ΦNS ± prophylactic 6-TG (20 µg) treatment. Results are from one representative experiment with 16 lesions enumerated per group (n = 8 animals). Data are shown as mean ± SD (**p ≤ 0.01, ***p ≤ 0.001, *p ≤ 0.05. Two-sided unpaired t-test). f Skin tissue was excised from mice infected with S. aureus or S. aureus purK::ΦNS 4 days post infection ± prophylactic 6-TG (20 µg) treatment and plated onto TSA to enumerate CFUs. Results are from one representative experiment with 16 lesions enumerated per group (n = 8 animals). Data are shown as mean ± SD (**p ≤ 0.01, ***p ≤ 0.001. Two-sided unpaired t-test). For a-d, numbers to the left of gels/blots are molecular mass markers (in kDa).
constant competition for space and nutrients. Indeed, it has been suggested that the presence of *S. chromogenes* offers protection against *S. aureus* infections in bovines36. The conservation of the *tgs* operon in *S. chromogenes* and other CoNS suggests that the genes have moved during competition in niches they co-occupy. For example, the CoNS that harbor the *tgs* operon colonize skin and mucosal surfaces of various mammals including humans, similar to *S. aureus* and are known to cause opportunistic infections24,39,40. The *tgs*-positive *S. chromogenes* and *S. epidermidis* strains that inhibit *S. aureus* growth produce at least tenfold more 6-TG into the culture supernatant than the two *tgs*-positive *S. capitis* strains. This difference would appear to account for the observed difference in the growth-inhibitory ability between the species, since the *S. capitis* *tgs* genes produce enough 6-TG to inhibit *S. aureus* growth when they are expressed from a multi-copy plasmid. Our ongoing studies seek to define the regulatory mechanism and signal(s) controlling expression of the operon in *S. capitis*.

Here, we showed that NUDIX domain-containing proteins are responsible for 6-TG biosynthesis. NUDIX domain proteins are widespread among microbes and have been implicated in bacterial pathogenesis41. Therefore, it is likely that microbes besides *Erwinia* and staphylococcal species also synthesize 6-TG. At this time, the enzymatic reactions required to synthesize 6-TG are unknown without confirmation of biochemical activity of the Tgs enzymes. Our bioinformatic analyses (Table 1) allow us to speculate that GTP can serve as an initial substrate. A combination of TgsC, TgsE, and/or TgsF may cleave the phosphates off GTP to generate guanosine. TgsA is predicted to release a sulfur group from a donor molecule (e.g., cysteine), which then likely serves as a substrate for TgsB, which we predict transfers it guanine. TgsD is a predicted efflux membrane protein and presumably exports 6-TG out of the cell, and likely also therefore provides self-resistance to the molecule. Interestingly, our data demonstrate that, despite possessing the *tgsD* gene, growth of recombinant *S. aureus* carrying the *tgs* operon is still slowed in comparison to strains carrying vector alone (Supplementary Fig. 3).

In this work, we show that bacteria expressing the *tgs* operon can reduce lesion formation in a subcutaneous *S. aureus* infection in a 6-TG-dependent manner during a co-infection. These data along with other studies demonstrate that CoNS on the skin can provide protection against infections caused by the more pathogenic *S. aureus* on the skin9,11,14. To demonstrate the therapeutic potential of 6-TG, we showed that the pure compound can be used to prophylactically treat *S. aureus* skin infections. Our data suggest that 6-TG acts therapeutically by reducing the overall amount of toxin that *S. aureus* may secrete during infection. We show that the molecular basis for the therapeutic effect of 6-TG is likely due to its...
ability to abrogate purine biosynthesis, which subsequently reduces ribosome synthesis and toxin production. Moreover, 6-TG downregulates transcription of the global virulence regulator agr, further reducing toxin production. By inhibiting de novo purine biosynthesis, we show that 6-TG can act as an anti-virulence compound in a subcutaneous S. aureus skin infection model as purine synthesis and toxin production are linked. These data reveal purine biosynthesis as an attractive drug target for treatment of MRSA infections, as targeting this pathway significantly affects toxin production, which is important for many types of S. aureus infections at different sites of the body. Thus, it will be interesting to determine whether 6-TG can also be used to reduce disease severity and/or bacterial burden in other models of infection in future studies. Indeed, Lan et al. have shown that 6-TG can reduce S. aureus burden in a systemic infection in mice. Moreover, it will be important to test other nucleobase analogs against S. aureus to potentially expand our repertoire of antimicrobials and/or anti-virulence compounds to treat MRSA infections.

Like other thiopurines, 6-TG is a pro-drug that enters the purine salvage pathway and is converted into its active form, 6-thioguanosine monophosphate, by the enzyme hypoxanthine-guanine phosphoribosyl transferase (HPRT) in humans. Once converted into an active metabolite, 6-TG is thought to block purine synthesis and be incorporated into DNA, causing cytotoxic effects in eukaryotic cells. Whether 6-TG affects bacteria by exerting mutagenic effects is currently unknown. However, Sun et al. showed that 6-TG interacts with HPRT to block purine salvage. This suggests that 6-TG may also antagonize S. aureus through the purine salvage pathway by being activated by HPRT. We are currently investigating the molecular targets of 6-TG and to identify determinants that make S. aureus susceptible to 6-TG.

It is well known that certain antibiotics can select for agr mutations and S. aureus strains harboring these mutations become more resistant to these stresses and cause chronic infections. However, we currently have no evidence to suggest that 6-TG selects for the emergence of these mutants or that agr-negative strains are resistant to 6-TG. In this study, we observed that the agr-negative strain RN4220 is susceptible to the growth-inhibitory effects of 6-TG. Future work will seek to identify mechanisms of resistance against 6-TG in S. aureus and how evolving resistance against this drug affects S. aureus physiology and metabolism.

It is becoming increasingly clear that many CoNS, including the species identified in this study that contain the igs operon, co-colonize with S. aureus and competition between these species for the same niches can provide protection for the host. This work reveals a previously unknown mechanism by which the relatively understudied CoNS can inhibit growth and virulence of more pathogenic bacteria like S. aureus. This, in turn, should spark interest in the discovery of additional genes synthesizing other nucleotide analogs that may be used by bacteria in inter-species bacterial warfare.

Methods

Bacterial strains and plasmids. Bacterial strains and plasmids are listed in Supplemental Table 1. Unless otherwise noted, strains were cultured at 37 °C with 200 RPM shaking. E. coli was grown in Luria broth (LB) or on LB agar containing 100-μg/mL ampicillin to maintain plasmids when necessary. S. aureus USA300 and RN4220 were grown in TSB or on TSB agar plates (TSA). Staphylococcal plasmids were maintained with growth in 10-μg/mL chloramphenicol when necessary.

Bacterial supernatant growth inhibition assays. Overnight cultures of S. chromogenes and S. aureus were grown in TSB for ~24 h. Cultures were pelleted at 21,000 g for 5 min and supernatants were filter-sterilized using a 0.22-μm syringe filter. The OD600 of S. aureus cultures was normalized to 1.0 and 6 μl (corresponding to 0.01 ODU, ~5 × 10^6 CFUs) were grown in a 1.0-mL mixture of TSB and either S. chromogenes or S. aureus spent culture supernatants (as indicated in figure or legend) in 13-mL tubes at 37 °C with 200 RPM shaking for 24 h. Bacterial cultures were serially diluted and plated onto TSA to enumerate CFUs at 24 h post inoculation.

S. chromogenes supernatant treatments. For the use of Amicon Ultra cen-trifugal filter units, filter-sterilized supernatants were centrifuged at 3620 g for 20 min to separate the supernatant into filtrate and concentrate. TSB was added to increase the concentrate volume to the original volume of the supernatant. For heat treatment, supernatants were filter-sterilized and incubated in a 95 °C heat block for 1 h. For proteinase K treatment, 10 μl of a 20-mg/ml proteinase K solution was added to 1 mL of filter-sterilized supernatant and incubated in a 37 °C heat block for 1 h. Proteinase K was inactivated at 95 °C for 30 min. For trypsin treatment, 20 μl of a 20-mg/ml trypsin solution was added to 1 mL of filter-sterilized supernatant and incubated in a 37 °C heat block for 1 h. Trypsin was inactivated at 95 °C for 30 min.

Fast protein liquid chromatography. Twenty milliliter of S. chromogenes -3-KDa supernatant was loaded on a Sigma-Aldrich Hitrap SP Fast Flow column on an Amersham Pharmacia Biotech AKTA FPLC system. Samples were eluted in a 0–50% gradient of solvent B (50-mM Tris pH 8.0) over solvent A (20-mM Tris pH 7.5). Five milliliter fractions were collected at a flow rate of 2.0 mL/min.

High performance liquid chromatography. Ten milliliter of the active fraction from FPLC was concentrated using a SpeedVac vacuum concentrator and re-suspended in 300-μl dH2O. Two hundred microliter of the suspension was injected into a preparative Waters Biorad C18 column on a Waters Breeze HPLC. Samples were eluted in a 0–100% gradient of solvent B (methanol or acetone) over solvent A (water or water with 0.1% trifluoroacetic acid). Two milliliter fractions were collected at a flow rate of 4.0 mL/min.

Liquid chromatography-mass spectrometry for identification of compounds. A 10-μl injection of each fraction was eluted from a Thermo Scientific Hypersil Gold C18 Column at 40 °C on a Thermo Scientific Ultimate 3000 UPLC, with a binary solvent system containing water with 0.1% (v/v) formic acid (solvent A) and acetonitrile containing 0.1% (v/v) formic acid (solvent B) at a 0.3-mL/min flow rate. The gradient initiated with a 1.0-min hold at 5% B. From 1.0 to 7.0 min, the gradient increased linearly to 98% B followed by a hold for 3 min. The gradient then decreased linearly to 5% B from 10–10.5 min and held at 5% B for 4.5 min. The Thermo Scientific Q Exactive mass spectrometer was operated using the following settings: Ion source, HESI II; spray voltage, 3.5 kV; sheath gas flow, 15; auxiliary gas, 5; spare gas, 2; capillary temperature, 320 °C; S-lens RF level, 50. A scan range of 100–1200 was used to identify ions in both positive and negative modes. An untargeted MS; experiment was performed using an isolation window of 1.0 m/z and a normalized collision energy of 30 (arbitrary units). Untargeted data processing was done using Thermo Compound Discoverer 2.1.

Identification of candidate inhibitory compounds. Each compound identified using mass spectrometry in every fraction was given a score based on its abundance in their respective fractions; a higher score signifies higher abundance. Compounds were not considered if they were not identified in all three experiments. Next, we divided the score from the fraction with the highest score (i.e., most concentrated) by the one with the lowest score (i.e., least concentrated) for each compound. The formula for each compound was calculated as follows: score ratio = (compound A highest score)/(compound A lowest score). A score ratio of a molecule approaching a value of 1 signifies an equal distribution of that compound between active fractions. Here, we chose to consider hits with a score ratio of 10 or less in all three experiments as potential candidates for the inhibitory molecule. We chose this cutoff for the score ratio under the assumption that the inhibitory compound was evenly distributed throughout the active fractions since inhibitory activity was equal between these fractions.

Whole-genome sequencing of genomic DNA. S. chromogenes genomic DNA was isolated by phenol–chloroform extraction. The extracted genomic DNA for H278/Tor was tagmented using the Nextera XT tagmentation kit according to manufacturer protocol. The tagmented products were sequenced on an Illumina Miniseq with paired-end sequencing (2 × 150 bp) at the University of Toronto. The extracted genomic DNA for H278P1, H279, JB98, and JB383 was tagmented using the Nextera tagmentation kit (Illumina) using a modified protocol. The tagmented products were sequenced on an Illumina NextSeq 550 with paired-end sequencing (2 × 150 bp) at the Microbial Genome Sequencing Center in Pittsburgh, PA. The “Pit” and “Tor” designations for H278 refer to the sequencing location for the isolates to differentiate between the two during downstream analyses. DNA sequence reads were trimmed using Trimmomatic version 0.36 with the following parameters: ILLUMINACLIP, Nextera:apE:2:30:10:8:true; LEADING, 20; TRAILING, 20; SLIDINGWINDOW, 4:20; MINLEN, 36. The reads were assembled using the SPAdes version 3.13 assembler.
in careful mode. Contigs for both the whole genome and the plasmid were annotated using Prokka version 1.1239.

Bioinformatic analyses of the 6-TG operon in Staphylococcus species. Draft and completed genomes of seven different Staphylococcus species (capitis, caprae, chromogenes, epidermidis, hominis, lugdunensis, and pseudintermedius) were downloaded from NCBI. The 6-TG operon and its homologs were identified using tBLASTn50 using translation table 11, with the S. chromogenes 6-TG operon used as the query sequence. Genomes that contained the operon are listed in Supplementary Data 1. The 6-TG operon and its homologs were extracted, and their nucleotide sequences were aligned in Geneious Prime 2020.1.2 (https://www.geneious.com) using the Geneious aligner and the default settings. The alignment was visualized in Geneious Prime 2020.1.2 (https://www.geneious.com). Expression analysis and comparisons were performed using DESeq232.

**Bioinformatic analyses of the 6-TG operon in Staphylococcus species.** Draft and completed genomes of seven different Staphylococcus species (capitis, caprae, chromogenes, epidermidis, hominis, lugdunensis, and pseudintermedius) were downloaded from NCBI. The 6-TG operon and its homologs were identified using tBLASTn50 using translation table 11, with the S. chromogenes 6-TG operon used as the query sequence. Genomes that contained the operon are listed in Supplementary Data 1. The 6-TG operon and its homologs were extracted, and their nucleotide sequences were aligned in Geneious Prime 2020.1.2 (https://www.geneious.com) using the Geneious aligner and the default settings. The alignment was visualized in Geneious Prime 2020.1.2 (https://www.geneious.com). Expression analysis and comparisons were performed using DESeq232.

---

**Bioinformatic analyses of the 6-TG operon in Staphylococcus species.** Draft and completed genomes of seven different Staphylococcus species (capitis, caprae, chromogenes, epidermidis, hominis, lugdunensis, and pseudintermedius) were downloaded from NCBI. The 6-TG operon and its homologs were identified using tBLASTn50 using translation table 11, with the S. chromogenes 6-TG operon used as the query sequence. Genomes that contained the operon are listed in Supplementary Data 1. The 6-TG operon and its homologs were extracted, and their nucleotide sequences were aligned in Geneious Prime 2020.1.2 (https://www.geneious.com) using the Geneious aligner and the default settings. The alignment was visualized in Geneious Prime 2020.1.2 (https://www.geneious.com). Expression analysis and comparisons were performed using DESeq232.
**Reporting summary.** Further information on research design is available in the Nature Research Reporting Summary linked to this article.

**Data availability.**

The raw sequence reads for the *S. chromogenes* ATCC43764 (H727Ftor, H727Fpu, H279), IP98 and IP383 isolates sequenced in this study can be found in the NCBI Sequence Read Archive under BioProject ID: PRJNA630769. RNA-seq data can be found in the NCBI Sequence Read Archive under BioProject ID: PRJNA695221. The authors declare that the data supporting the findings of this study are available within the paper and its supporting Supplementary information files. Source data are provided with this paper.

**Received:** 22 October 2020; **Accepted:** 1 March 2021; **Published online:** 25 March 2021

**References**

1. Lowy, F. D. *Staphylococcus aureus* Infections. *N. Engl. J. Med.* 339, 520–532 (1998).
2. Fair, R. J. & Tor, Y. Antibiotics and bacterial resistance in the 21st century. *Perspect. Med. Chem.* 25–64 https://doi.org/10.14377/PMC.14459 (2014).
3. Kennedy, A. D. et al. Epidemic community-associated methicillin-resistant *Staphylococcus aureus*: recent clonal expansion and diversification. *Proc. Natl Acad. Sci. USA.* 105, 1327–1332 (2008).
4. McAdam, P. R. et al. Molecular tracing of the emergence, adaptation, and transmission of hospital-associated methicillin-resistant *Staphylococcus aureus*. *Proc. Natl Acad. Sci. USA.* 109, 9107–9112 (2012).
5. Boucher, H. W. et al. Bad bugs, no drugs: new strategies for an armamentarium. *J. Antimicrob. Chemother.* 68, 515–540 (2013).
6. Moran, G. J. et al. Methicillin-resistant *S. aureus* infections among patients in the emergency department. *N. Engl. J. Med.* 372, 1254–1265 (2015).
7. Zetola, N., Francis, J. S., Nuermberger, E. L. & Bishai, W. R. Community-acquired methicillin-resistant *Staphylococcus aureus* infections in the United States. *Clin. Infect. Dis.* 50, 1209–1217 (2010).
8. Kennedy, A. D. et al. Targeting of alpha toxin monoclonal antibodies that reduce the severity of *Staphylococcus aureus* dermonecrosis and exhibit a correlation between affinity and potency. *Clin. Vaccine. Immunol.* 19, 377–385 (2012).
9. Papazoglou, G., Jafari, S. S., Papanastasiou, M. V. & Bishai, W. R. Coagulase-negative *Staphylococcus aureus* strains isolated from bovine milk. *Appl. Environ. Microbiol.* 83, 01015–01017 (2017).
10. Zipperer, A. et al. Human commensals producing a novel antibiotic impair pathogen colonization. *Nature* 535, 511–516 (2016).
11. Nakatsui, T. et al. Antimicrobials from human skin commensal bacteria protect against *Staphylococcus aureus* and are deficient in atopic dermatitis. *Sci. Transl. Med.* 9, eaal4680 (2017).
12. Bitschar, K. et al. Luguin amplifies innate immune responses in the skin in synergy with host- and microbiota-derived factors. *Nat. Commun.* 10, 2730 (2019).
13. Canovas, J. et al. Cross-talk between Staphylococcus aureus and other *Staphylococcus* species via the agr quorum sensing system. *Front. Microbiol.* 7, 1732 (2016).
14. Brown, M. M. et al. Novel peptide from commensal *Staphylococcus chromogenes* simulates methicillin-resistant *Staphylococcus aureus* quorum sensing and protects host skin from damage. *Antimicrob. Agents Chemother.* 64, e00172–02020 (2020).
15. Braem, G. et al. Antibacterial activities of coagulase-negative *Staphylococcus* from bovine teat apex skin and their inhibitory effect on mastitis-related pathogens. *J. Appl. Microbiol.* 116, 1084–1093 (2014).
16. De Vliegher, S. et al. In vitro growth inhibition of major mastitis pathogens by *Staphylococcus chromogenes* originating from teat apices of dairy heifers. *Veter. Microbiol.* 101, 215–221 (2004).
17. Rahman, S., Shekarforoush, S., Hosseinizadeh, S., Torriani, S. & Gatto, V. Antibacterial spectrum activity of bacteriocinogenic *Staphylococcus chromogenes* strains isolated from goat and sheep milk. *J. Dairy Sci.* 102, 2928–2940 (2019).
18. Włodarska, M. et al. Indoleacrylic acid produced by commensal *Peptostreptococcus* species suppresses inflammation. *Cell Host Microbe* 22, 25–37,e6 (2017).
19. Azuma, T., Saito, S., Shiraishi, R., Dohi, Y., Jikumaru, Y., Chiba, Y. & Yamanaka, M. N-Deacetyl-N-methylpentosamine inhibits the growth of *Staphylococcus aureus* via targetting of the PmrA-PmrB regulon. *J. Med. Chem.* 51, 9911–9919 (2008).
20. Lan, L., Cheng, A., Dunman, P. M., Missiakas, D. & He, C. Golden pigment production and virulence gene expression are affected by metabolisms in *Staphylococcus aureus*. *Cell Host Microbe* 22, 35–46 (2017).
21. Zitouni, N. et al. Inhibitory activity of 6-Thioguanine, 6-Mercaptopurine, and 8-Azaguanine. *Cancer Res.* 22, 3077 (1962).
Acknowledgements
We would like to thank members of the Heinrichs laboratory for constructive comments on the manuscript. We thank Drs Barry Kreiswirth, John McCormick, Martin McGavin, and J. Scott Weese for strains. D.C. and S.R.D. were supported by Ontario Graduate Scholarships. S.R.D. was also supported by a fellowship from the Department of Biochemistry, University of Toronto. This work was supported by project Grants PJT-153308 (to D.E.H.) and PJT-148819 (to A.W.E.) from the Canadian Institutes of Health Research.

Author contributions
Conceptualization: D.C., M.I.G., V.G.-O., R.S.F., and D.E.H.; methodology: D.C., M.I.G., V.G.-O., S.R.D., and D.E.H.; investigation: D.C., M.I.G., V.G.-O., S.R.D., R.S.F., A.W.E., and D.E.H.; resources: A.W.E. and D.E.H.; funding acquisition: A.W.E. and D.E.H.; writing: D.C. and D.E.H.; supervision: A.W.E. and D.E.H.

Competing interests
The authors declare no competing interests.

Additional information
Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41467-021-22175-3.

Correspondence and requests for materials should be addressed to D.E.H.

Peer review information Nature Communications thanks Lorena Tuchscherr and the other, anonymous, reviewers for their contribution to the peer review of this work.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021